Last day of trading in subscription rights in IRLAB’s rights issue

July 14, 2025

Today, 14 July 2025, is the last day of trading in the subscription rights issued in connection with IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of new shares of series A with preferential rights for existing shareholders, which was resolved by the Board of Directors on 24 June 2025 by virtue of the authorization from the Annual General Meeting (the “Rights Issue”). Subscription rights that are not sold by today, 14 July 2025, or exercised for subscription of shares in the Rights Issue no later than 17 July 2025, will expire worthless. Please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

Today, 14 July 2025, is the last day of trading in the subscription rights issued in connection with IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of new shares of series A with preferential rights for existing shareholders, which was resolved by the Board of Directors on 24 June 2025 by virtue of the authorization from the Annual General Meeting (the “Rights Issue”). Subscription rights that are not sold by today, 14 July 2025, or exercised for subscription of shares in the Rights Issue no later than 17 July 2025, will expire worthless. Please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.

Summary of the Rights Issue

  • The Rights Issue comprises a maximum of 38,901,304 shares of series A.
  • Upon full subscription, IRLAB will receive approximately SEK 136 million before deduction of issue-related costs.
  • The subscription price is SEK 3.50 per share.
  • The Rights Issue is covered by subscription undertakings amounting to approximately 33 percent, corresponding to approximately SEK 44 million. The Company has furthermore entered into agreements on guarantee undertakings which amounts to a total of approximately SEK 71 million, corresponding to approximately 52 percent of the Rights Issue.
  • In total, approximately 85 percent of the Rights Issue is secured by subscription and guarantee undertakings.
  • Anyone who was registered in the share register as a shareholder in IRLAB on the record date of 1 July 2025 received one (1) subscription right for each (1) share held, regardless of shares series.
  • Four (4) subscription rights entitle for subscription of three (3) newly issued shares of series A.
  • Shareholders who choose not to participate in the Rights Issue will have their ownership diluted by up to approximately 42.9 percent but will have the opportunity to compensate themselves financially for the dilution effect by selling their subscription rights.
  • Full terms and conditions for the Rights Issue and other information about the Company are set out in the Appendix IX information document published by the Company on 2 July 2025.

The information document and other information about the Rights Issue is available on the Company’s and Eminova Fondkommission AB’s respective websites, www.irlab.se and www.eminova.se.

Indicative time plan
The following time plan for the Rights Issue is preliminary and subject to change.

Subscription period 3 July 2025 – 17 July 2025
Trading in paid subscribed shares (BTA) 3 July 2025 – week 31, 2025
Expected day for announcement of the outcome 21 July 2025

Advisers
MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue.